Regimmune Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $6M

  • Investors
  • 33

Regimmune General Information

Description

Developer of immune regulatory therapeutics designed to develop novel therapeutics for a range of immune diseases and disorders. The company's technology focuses on therapeutic areas to target immune tolerance against specific disease-causing antigens through the induction of regulatory T cells, enabling patients to avail innovative and proper treatment for immune disorders.

Contact Information

Website
www.regimmune.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Floor 8 41 Nanjing West Road
  • Datong District
  • Taipei, 103
  • Taiwan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 8 Floor 8 41 Nanjing West Road
  • Datong District
  • Taipei, 103
  • Taiwan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series E) 07-Apr-2017 $6M Completed Clinical Trials - General
7. Later Stage VC (Series D) 14-Feb-2014 Completed Clinical Trials - General
6. Later Stage VC (Series C) 28-Mar-2012 Completed Clinical Trials - General
5. Grant 08-Dec-2008 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 06-May-2008 Completed Pre-Clinical Trials
3. Grant 07-Aug-2007 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 21-Feb-2007 $4.2M $5.8M Completed Pre-Clinical Trials
1. Seed Round 15-Aug-2006 $1.6M $1.6M Completed Generating Revenue
To view Regimmune’s complete valuation and funding history, request access »

Regimmune Patents

  • 42

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Regimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026086484-A Cd1d ligand compound-containing liposome preparation having improved pharmacokinetics Pending 04-Dec-2020
AU-2021392472-A1 Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics Pending 04-Dec-2020
AU-2021392472-A9 Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics Pending 04-Dec-2020
CA-3201106-A1 Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics Pending 04-Dec-2020
EP-4257140-A1 Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics Pending 04-Dec-2020 A61K9/127
To view Regimmune’s complete patent history, request access »

Regimmune Investors (33)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hiroshima Venture Capital Venture Capital Minority
Iyo-Gin Capital Venture Capital Minority
Leading Capital (Tokyo) Real Estate Minority
Miyako Capital Venture Capital Minority
Ogaki Kyoritsu Bank Corporation Minority
You’re viewing 5 of 33 investors. Get the full list »

Regimmune Acquisitions (1)

Regimmune’s most recent deal was a Merger/Acquisition with KIJI Therapeutics. The deal was made on 27-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
KIJI Therapeutics 27-Mar-2025 Merger/Acquisition Biotechnology
To view Regimmune’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Regimmune Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
KIJI Therapeutics Paris, France 2023

Regimmune FAQs

  • When was Regimmune founded?

    Regimmune was founded in 2006.

  • Where is Regimmune headquartered?

    Regimmune is headquartered in Taipei, Taiwan.

  • What industry is Regimmune in?

    Regimmune’s primary industry is Drug Discovery.

  • Is Regimmune a private or public company?

    Regimmune is a Private company.

  • What is Regimmune’s current revenue?

    The current revenue for Regimmune is .

  • How much funding has Regimmune raised over time?

    Regimmune has raised $34.5M.

  • Who are Regimmune’s investors?

    Hiroshima Venture Capital, Iyo-Gin Capital, Leading Capital (Tokyo), Miyako Capital, and Ogaki Kyoritsu Bank are 5 of 33 investors who have invested in Regimmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process